DRKS00006321已完成不适用
PROPHET: Prospective clinical and pharmacoeconomic outcomes study of different first-line antiretroviral treatment strategies - PROPHET-Study
DAGNÄ e.V. (Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V.) vertreten durch Dr. med. Knud Schewe und Dr. med. Stefan Klauke0 个研究点目标入组 444 人开始时间: 2016年2月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 444
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •1. The patient´s age at the date of inclusion is >18 years
- •2. Chronic HIV-infection, to date without HIV-treatment and indication of therapy start
- •3. Signed patient informed consent
- •4. Planned treatment initiation with backbone consiting of TDF+FTC or ABC+3TC in combination with a third antiretroviral drug
- •5. The third substance is either a Non-nucleosidale-Reverse-Transcriptase-Inhibitor NNRTI: (Efavirenz, Nevirapin, Rilpivirin), a boosted Protease-Inhibitor (PI/r: Darunavir/r, Lopinavir/r, Atazanavir/r, Fosamprenavir/r) or Integrase-Inhibitor (INI: Raltegravir, Elvitegravir/c, Dolutegravir).
排除标准
- •1. Initiation of antiretroviral therapy which is not based on a backbone of TDF+FTC or ABC/3TC in combination with a NNRTI, PI/r or INI.
- •2. Acute HIV-infection, seroconversion
- •3. Prior use of antiretroviral drugs (a short-term therapy within the scope of a mother-to-child-transmission-prophylaxis is allowed)
研究者
相似试验
招募中
不适用
Treatment of cutaneous leishmaniasis with pentamidine isethionate in Suriname; a comparison study between two treatment regimes, 3 days vs 7 days.NL-OMON23868Koninklijk Instituut voor de Tropen (KIT)220
进行中（未招募）
1 期
Efficacy, safety and pharmaco-economic assessment of secondary long term prophylaxis with highly purified, standardized, doubly virus inactivated FVIII/VWF concentrates in patients with severe, inherited VWD and frequent bleedings - PRO.WIpatients with severe inherited VWD unresponsive to DDAVP and with frequent bleedingsMedDRA version: 8.1Level: PTClassification code 10047715Term: Von Willebrand's diseaseEUCTR2006-001383-23-ITFONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI24
进行中（未招募）
1 期
Efficacy, safety and pharmaco-economic assessment of secondary long term prophylaxis with highly purified, standardized, doubly virus inactivated FVIII/VWF concentrates in patients with severe, inherited VWD and frequent bleedings.Severe, inherited von Willebrand disease (VWD) and frequent bleedingsMedDRA version: 14.1 Level: PT Classification code 10047715 Term: Von Willebrand's disease System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2006-001383-23-GBProf Flora Peyvandi, MD24
进行中（未招募）
1 期
Efficacy, safety and pharmaco-economic assessment ofsecondary long term prophylaxis with highly purified, standardized, doubly virus inactivated FVIII/VWF concentrates in patients with severe, inherited VWDand frequent bleedingsPatients with severe, inherited Von Willebrand’s disease and frequent bleedingsMedDRA version: 16.0Level: PTClassification code 10047715Term: Von Willebrand's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2006-001383-23-DEFondazione IRCCS Cà Granda Ospedale Maggiore Policlinico24
进行中（未招募）
1 期
Efficacy, safety and pharmaco-economic assessment of secondary long term prophylaxis with highly purified, standardized, doubly virus inactivated FVIII/VWF concentrates in patients with severe, inherited VWD and frequent bleedings.Severe, inherited von Willebrand disease (VWD) and frequent bleedingsMedDRA version: 14.1Level: PTClassification code 10047715Term: Von Willebrand's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2006-001383-23-ESFondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico24